Terns Pharmaceuticals to Participate in the Cowen 42nd Annual Healthcare Conference
February 28, 2022 16:05 ET
|
Terns Pharmaceuticals, Inc.
FOSTER CITY, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...
Terns Pharmaceuticals Appoints Jeffrey R. Jasper, Ph.D., as Senior Vice President, Head of Research and Promotes Diana Chung to Senior Vice President, Chief Development Officer
January 06, 2022 07:05 ET
|
Terns Pharmaceuticals, Inc.
FOSTER CITY, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...
Terns Pharmaceuticals to Present at 40th Annual J.P. Morgan Health Care Conference
January 03, 2022 16:05 ET
|
Terns Pharmaceuticals, Inc.
FOSTER CITY, Calif., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...
Terns Pharmaceuticals Reports Third Quarter 2021 Financial Results and Corporate Highlights
November 15, 2021 16:05 ET
|
Terns Pharmaceuticals, Inc.
-Top-line data readout from TERN-201 (VAP-1) clinical trial in NASH expected in 1Q 2022 -Positive top-line data from TERN-501 (THR-β) demonstrated clinical proof of concept, enabling the planned...
Terns Pharmaceuticals Highlights Positive Clinical Data from Multiple NASH Programs at AASLD The Liver Meeting® Digital Experience 2021
November 12, 2021 07:05 ET
|
Terns Pharmaceuticals, Inc.
Oral presentation of data from Phase 2a LIFT Trial of TERN-101, demonstrating differentiated safety and efficacy profiles 12 weeks of TERN-101 treatment significantly decreases cT1, a marker of...
Terns Reports Positive Top-line Results from Phase 1 Proof of Concept Clinical Trial of THR-β agonist TERN-501
November 09, 2021 16:05 ET
|
Terns Pharmaceuticals, Inc.
TERN-501 demonstrated significant effects on key pharmacodynamic marker of THR-β engagement linked to NASH histologic efficacy TERN-501 was generally safe and well-tolerated with predictable...
Terns Pharmaceuticals to Present Positive Clinical Data on NASH Programs at AASLD The Liver Meeting® Digital Experience 2021
October 18, 2021 16:05 ET
|
Terns Pharmaceuticals, Inc.
FOSTER CITY, Calif., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...
Terns Pharmaceuticals to Present at H.C. Wainwright 5th Annual NASH Investor Conference
October 05, 2021 16:05 ET
|
Terns Pharmaceuticals, Inc.
FOSTER CITY, Calif., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...
Terns Appoints Veteran Biopharmaceutical Executive Ann E. Taylor, M.D. to Board of Directors
September 28, 2021 16:05 ET
|
Terns Pharmaceuticals, Inc.
FOSTER CITY, Calif., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...
Terns Completes Part 1 Enrollment of AVIATION Phase 1b NASH Clinical Trial of VAP-1 Inhibitor TERN-201
September 08, 2021 07:05 ET
|
Terns Pharmaceuticals, Inc.
- TERN-201 is a highly selective VAP-1 inhibitor intended to address chronic liver inflammation and fibrosis in NASH - Top-line TERN-201 NASH clinical data expected in 1Q 2022 FOSTER CITY, Calif.,...